Frontiers | Current Knowledge on Pancreatic Cancer
Gemcitabine is the standard chemotherapeutic drug for patients with advanced pancreatic cancer after a phase III trial in 1997 that demonstrated a modest survival advantage of this agent over 5-FU (median survival 5.65 versus 4.41 months, respectively).
Not available in source_content.
This sentence highlights the current standard of care and the limited survival benefit of gemcitabine in advanced pancreatic cancer, underscoring the need for more effective therapies.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.